NCT04334512

A Study of Quintuple Therapy to Treat COVID-19 Infection

A Randomized, Double-Blind, Placebo-Controlled Phase IIa Study of Quintuple Therapy to Treat COVID-19 Infection

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 118 (actual)
• Sponsor: ProgenaBiome · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a Phase II interventional study will test the efficacy of quintuple therapy (Hydroxychloroquine, Azithromycin, Vitamin C, Vitamin D, and Zinc) in the treatment of patients with COVID-19 infection).

Detailed description

In this study patients will be treated with a combination therapy to determine if this combination can effectively treat COVID-19. Treatment will last ten days. The study will last 24 weeks.

Conditions

• COVID-19
• Corona Virus Infection
• Coronavirus-19
• Sars-CoV2

Interventions

Type	Name	Description
DRUG	Hydroxychloroquine	Treatment with hydroxychloroquine
DRUG	Azithromycin	Treatment with azithromycin
DIETARY_SUPPLEMENT	Vitamin C	Treatment with vitamin C
DIETARY_SUPPLEMENT	Vitamin D	Treatment with vitamin D
DIETARY_SUPPLEMENT	Zinc	Treatment with Zinc

Timeline

• Start date: 2020-06-22
• Primary completion: 2024-02-27
• Completion: 2024-02-27
• First posted: 2020-04-06
• Last updated: 2024-02-29

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study